Article Figures & Data
Tables
Risk factor Risk for any stroke (95% confidence interval) Recommendations to mitigate risk Adverse pregnancy outcomes Detailed obstetric history for all individuals Hypertensive disorders of pregnancy RR 1.74 (1.45–2.10)2 Gestational diabetes RR 1.45 (1.29–1.63)2 Regular screening for hypertension, weight, smoking status, diabetes, and hyperlipidemia Preterm birth RR 1.65 (1.51–1.79)2 Stillbirth HR 1.38 (1.11–1.71)2 Placental abruption RR 1.70 (1.19–2.42)2 Comprehensive lifestyle modificationa Recurrent pregnancy loss HR 1.42 (1.05–1.90)2 Small-for-gestational-age HR 1.30 (1.0–1.70)2 Preeclampsia RR 1.81 (1.29–2.55)12 Premature menopause RR 1.25 (1.04–1.51)20 Estrogen replacement therapy until age of natural menopause HR 1.69 (1.37–2.08)23 HR 1.23 (1.12–1.36)24 Lipid and diabetes screen at time of premature menopause diagnosis Early menopause HR 1.57 (1.43–1.71)23 Annual screening for hypertension, weight, smoking status, and hyperlipidemia Comprehensive lifestyle modificationa Endometriosis HR 1.34 (1.10–1.62)33
HR 1.20 (1.11–1.30)34
HR 1.17 (1.07–1.29)35
HR 1.18 (1.12–1.23)36b
HR 1.13 (1.03–1.24)38bAvoid treatments that induce premature and early menopause when possible Consider combined hormonal contraceptive with ethinyl estradiol ≤ 30 μg or progestin-only option Regular screening for hypertension, weight, smoking status, and hyperlipidemia Comprehensive lifestyle modificationa Hormonal contraceptives Consider combined hormonal contraceptive with ethinyl estradiol ≤ 35 μg or progestin-only option or nonhormonal contraceptive in patients with elevated baseline risk for stroke45 Progestin-only contraceptives Odds ratio 0.96 (0.70–1.31)47 Combined hormonal contraceptive with ethinyl estradiol ≥ 50 μg No longer in use due to unacceptable risk48 Combined hormonal contraceptive with ethinyl estradiol ≤ 20 μg, 30–40 μg Incidence rate ratio 1.77 (1.62–1.93)48 Regular screening for hypertension, weight, smoking status, and hyperlipidemia
Comprehensive lifestyle modificationa






